About the Company
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SIOX News
Sio Gene Therapies Inc. (SIOX)
Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call ...
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies ...
Megatrends: Gene Therapy and Editing
Investors often like to be on the cutting edge of new developments, and it doesn't get much more cutting edge than gene therapy and editing. The ability to make changes to a person's DNA – the ...
Positive Clinical Trials Bolster Buy Rating for Taysha Gene Therapies
Taysha Gene Therapies (TSHA) Company Description: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and ...
ONCT Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical ...
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
Zeit Aktuelle Nachrichten Fr Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha ...
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for ...
Sio Gene Therapies Inc. (SIOX)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Taysha Gene Therapies Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Sio Gene Therapies Inc (SIOX)
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Technology, Oil & Gas and Consumer Services sectors propelled shares higher. At the close in... Pre-Open Stock ...
Loading the latest forecasts...